Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

ardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... N.J. , Nov. 21, 2014  PTC Therapeutics, Inc. ... the 2014 Legend of Technology Award for Vision, Innovation, and ... Ph.D., Chief Executive Officer. This award recognizes an individual who ... New Jersey for several decades. ... Technology Award," stated Stuart Peltz , Ph.D., CEO of ...
(Date:11/21/2014)... IRVINE, Calif. , Nov. 20, 2014  Edwards ... leader in the science of heart valves and hemodynamic ... corporate giving in 2014 to support a strong launch ... Heartbeat Matters , and to improve the global communities ... In 2014, Edwards, global corporate giving will exceed $8 ...
(Date:11/21/2014)... , Nov. 20, 2014 /CNW Telbec/ - KLOX ... announce the following appointments: Todd ... in the newly created role of Chief Commercial Officer, ... system using topical photoconverter gel for the treatment of ... and traumatic wounds, recently approved in Europe ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4
... , , HOUSTON , ... 16-year-old Francesco "Frank" De Santiago. On January 29 , ... transplant operation at Texas Children,s Heart Center . De ... child ever discharged from a pediatric hospital with an implanted ...
... , , KINGWOOD, Texas , Feb. ... announced today that the company has formally offered to purchase ... on selling in the chronic pain management medical sector. The ... not be identified until IMAI has a signed letter of ...
Cached Medicine Technology:Texas Children's Hospital Discharges History-Making Teen Patient Again; This Time With a Transplanted Heart Replacing Mechanical Device 2Texas Children's Hospital Discharges History-Making Teen Patient Again; This Time With a Transplanted Heart Replacing Mechanical Device 3International Merchant Advisors, Inc. Offers to Invest in Pharmaceutical Chain 2
(Date:11/23/2014)... 23, 2014 Wright & Schulte LLC ... Ohio and West Virginia residents who allege that they ... disorders due to drinking C8 contaminated water released ... Virginia. According to the C8 complaints, the plaintiffs were ... or lived in at least one of the six ...
(Date:11/22/2014)... November 23, 2014 Cancer researchers in ... connection between intercellular communication tunnels and the growth and ... full story on the Surviving Mesothelioma website. ... the University of Minnesota have just released their study ... and materials between cells. They found that mesothelioma ...
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in ... its new collection of bamboo mats ; the new ... off. , According to the sales manager of ... it a highly renewable resource. Their bamboo mats are 100% ... which comes from natural bamboo with caramel bamboo strips. ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 In order to ... new promotion of cocktail party dresses. The business knows that ... in social occasions. , Now, the party dresses ... to 70% off. As the leading company in fashion industry, ... favorite outfit for every customer. So it always raises the ...
(Date:11/22/2014)... SATURDAY, Nov. 22, 2014 (HealthDay News) -- The wide ... can pose a threat for people with food allergies, ... there are so many types of food allergies that ... over the holidays," Dr. Guha Krishnaswamy, director of allergy ... said in a hospital news release. "If you ...
Breaking Medicine News(10 mins):Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 2Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 3Health News:40 C8 Lawsuit Claims Filed By Wright & Schulte LLC Alleged Serious Illness Due To C8 Contaminated Water In Ohio And West Virginia 4Health News:Study Links Cellular ‘Tunnels’ to Mesothelioma Proliferation, According to Surviving Mesothelioma 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:'Tis the Season of Challenges for Those With Food Allergies 2
... Remain to Vote on the Proposed Merger, SOUTH SAN ... Dear VaxGen Stockholder, March 28th marks the date ... stockholder vote on the proposed VaxGen-Raven,merger. Your vote is important. ... votes cast in person or by proxy at the VaxGen ...
... March 20 Arthur J. Gallagher &,Co. ... Solutions, LLC,headquartered in Fort Washington, Pennsylvania. Terms ... in 2002, Healthcare Risk Solutions, LLC is ... insurance,products, associated risk mitigation consulting services and ...
... haze, scientists say , , THURSDAY, March 20 (HealthDay News) ... an important contributor to smog. , This chemical reaction ... dioxide (NO2) in "excited" states -- was long assumed ... University of California, San Diego, conclude that it,s actually ...
... Peake: Health Care Closer for Veterans, WASHINGTON, March ... access to world-class health care under,a Department of Veterans ... 2008. Secretary of Veterans Affairs Dr. James B. Peake ... Kentucky,Illinois, Indiana, Oklahoma, Tennessee and Washington., "VA is ...
... a proactive follow-up care program designed to help ... of life, PALO ALTO, Calif., March 20 ... it is offering oncology treatment,centers a way to provide ... quality of life. Varian is teaming with,Cogent Health Solutions ...
... people felt better dispersing gifts than buying things for themselves , , ... buy happiness, at least when you spend it on others. ... 21 issue of Science . It found that spending ... , What,s more, most people seemed unaware of this ...
Cached Medicine News:Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 2Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 3Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 4Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 5Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 6Health News:VaxGen Provides Updates and Encourages Stockholders to Vote In Favor of Proposed Merger With Raven 7Health News:Smog's Origins Get Clearer 2Health News:VA to Open 14 New Clinics in Seven States 2Health News:Varian Medical Systems Teams With Cogent Health Solutions to Offer Case Management Software for Cancer Survivorship 2Health News:Varian Medical Systems Teams With Cogent Health Solutions to Offer Case Management Software for Cancer Survivorship 3Health News:Give and Be Happy 2
... The ACON PSA Semi-Quantitative Prostate Specific Antigen ... are lateral flow tests in strip and ... Prostate Specific Antigen (PSA). The tests are ... cut-off values, and all come with a ...
Remote Control Vision Tester Can Administer Basic,Distance Vision Tests in Less Than 2 Minutes....
... Increase profitability by ... with simple test,sequences ... administered by ancillary ... than 5 minutes. ...
Holladay Contract Acuity Test provides a more sensitive evaluation for testing visual functions than standard acuity charts....
Medicine Products: